February 2, 1963

Successful Treatment of Cerebral Mucormycosis with Amphotericin B

Author Affiliations

New Haven, Conn.
From the Department of Medicine, Yale University School of Medicine.

JAMA. 1963;183(5):370-372. doi:10.1001/jama.1963.63700050034023a

RECENT REPORTS of recovery from mucormycosis following the appropriate therapy1,2 have stimulated renewed interest in the disease. Mucormycosis is caused by tissue invasion of saprophytic fungi of the genus Mucor. The disease occurs in patients who have debilitating diseases, or who have received antibiotics, steroids, or anti-tumor agents, and is particularly prone to develop in patients with diabetic acidosis. Forty-two percent of the cases in a recent review of mucormycosis3 were diabetic. Cerebral mucormycosis, the most common form of the disease, is associated with an extremely high mortality. Only six survivals1,4-7 have been reported, and all of those described have been left with residual deficits (see table).

The present case is of interest because the diagnosis was made early on the basis of certain previously described criteria8,9 and therapy begun with amphotericin B. Despite disturbing side effects of the drug, therapy was continued, and the patient

First Page Preview View Large
First page PDF preview
First page PDF preview